News Trastuzumab Duocarmazine Tried in HER2+ Breast Cancer by Medscape • 2024/10/31 • 0 Comments Patients with unresectable locally advanced or metastatic HER2+ breast cancer were randomly assigned to receive trastuzumab duocarmazine or a physician’s choice. Medscape Medical News